ATS 2024 Final Program

Click on the session title to view the speakers

322

WEDNESDAY • MAY 22

825 Improved Lung Function and Asthma Control Observed With Rademikibart in Patients With Moderate-to-Severe Uncontrolled Asthma (CBP-201-WW002)

709 Implementation of a State-wide Undesignated Stock Inhaler Program in Illinois 710 Characterization of Patients With Severe Asthma Who Initiated Biologic Treatment Within £ 90 and >90 Days After Biologic Eligibility 711 Real-world Patient Characteristics and Factors Associated With Biologic Prescriptions in Asthma Patients Eligible for Add-on Biologic Therapies 712 Real World Corticosteroid Effect of Anti-IL-5/5R a in Eosinophilic Asthma 713 Reduction of Systemic Corticosteroid (SCS) Related Complications With Mepolizumab in Severe Asthma: A Real-World Assessment 714 Social Determinants of Prescribing Omalizumab in Asthma 715 Assessing the Effectiveness of the Community Asthma Program in Enhancing Pediatric Asthma Management on the Navajo Nation 716 Is a Shared Decision-making Intervention Developed for Adults With Asthma Appropriate for Early Adolescents With Asthma and Their Caregivers? Results of Breathe-peds Focus Groups 717 Patient Experiences During Acute Exacerbation of Asthma: Survey Results 718 International Variation in Exacerbation Rates in Patients With Severe Asthma 719 Towards a Patient-centric Definition of Asthma Remission: An Interim Analysis of a Multi-country, Qualitative Study 720 Promoting Evidence-based Asthma Care Using Digital Knowledge Translation Tools - Impact of the Provider Asthma Assessment Form 721 The Asthma Medication Ratio Performance Measure Fails to Measure Asthma Care in the Majority of Patients With Poor Asthma Control 722 The Invisible Threads of Asthma: Exploring the Link Between Asthma, Mental Health, and Social Participation in Brazilian Adults 723 General Practice (GP) Text Messaging Support for

BEHAVIORAL • CLINICAL POSTER DISCUSSION SESSION

D22 ADVANCES IN HEALTH SERVICES RESEARCH IN ASTHMA 8:15 a.m. - 10:15 a.m. San Diego Convention Center Room 30C-E (Upper Level) Poster Viewing 8:15-9:00 Discussion 9:00-10:15 701 Advancing Equity in Mobile Health Tools for Asthma: A Focus Group Study of Hispanic and Latinx Community Perspectives 702 Association of Cardiovascular Disease, Pulmonary Embolism, and Pneumonia With Inhaled Corticosteroid Use in Asthma: A UK Cohort Study 703 Cost Analyses of an As-needed 60-actuation Vs. 120-actuation Budesonide-Formoterol pMDI for Patients With Mild Asthma From a United States Payor Perspective 704 Development and Feasibility of Provider Support 705 Trends and Factors Influencing Inhaled Corticosteroid (ICS) Adherence: Real-world Data From Multi-ethnic Asian Asthma Cohort 706 Temporal Trend of Inhaled Corticosteroid (ICS) and Short-Acting Beta 2 Agonist (SABA) Prescription Patterns: Analysis From a Real-World Multi-Ethnic Asian Asthma Cohort 707 A Real-World Data Analysis of the Trends and Variables Associated With Excessive Short-Acting Beta2 Agonist (SABA) Dispensing Among a Multi-Ethnic Asian Asthma Cohort 708 Reducing Short Acting Beta2 Agonist (SABA) Prescription Refills in Specialist Treated Asthma: A Quality Improvement Initiative Materials to Implement As-needed Inhaled Corticosteroid Therapy for Mild Asthma in the Community Practices

Medication Adherence in Asthma and COPD Patients: A Randomised Controlled Trial

ATS 2024 • San Diego, CA